sonar-pro
Permits stability data submission for pharmaceutical products at 25°C/60% relative humidity (RH) when supported by accelerated stability studies.
{
  "id": "9f7b7f0f-c701-484a-9144-ebffbb64ff9f",
  "choices": [
    {
      "finish_reason": "stop",
      "index": 0,
      "logprobs": null,
      "message": {
        "content": "{\"answer\":\"NO\",\"note\":\"The Philippines, as an ASEAN member, generally follows the ASEAN Guidelines on Stability Study, which require long-term stability data at 30°C/75% RH for products intended for Climatic Zone IVa (including the Philippines). The ASEAN guideline states that if submitted data is based on less stressful conditions like 25°C/60% RH, it must be accompanied by supportive data at the specified higher conditions[5]. Accelerated stability studies (e.g., 40°C/75% RH) are intended to supplement but not replace real-time/long-term data at the required conditions. Therefore, submission of stability data solely at 25°C/60% RH, even with accelerated data, is not sufficient for the Philippines unless specifically justified and accepted case-by-case by the regulatory authority, which is not the general rule[5].\"}",
        "refusal": null,
        "role": "assistant",
        "annotations": null,
        "audio": null,
        "function_call": null,
        "tool_calls": null
      },
      "delta": {
        "role": "assistant",
        "content": ""
      }
    }
  ],
  "created": 1755743869,
  "model": "sonar-pro",
  "object": "chat.completion",
  "service_tier": null,
  "system_fingerprint": null,
  "usage": {
    "completion_tokens": 177,
    "prompt_tokens": 31,
    "total_tokens": 208,
    "completion_tokens_details": null,
    "prompt_tokens_details": null,
    "search_context_size": "low",
    "cost": {
      "input_tokens_cost": 0.0,
      "output_tokens_cost": 0.003,
      "request_cost": 0.006,
      "total_cost": 0.009
    }
  },
  "citations": [
    "https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf",
    "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
    "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC11858995/",
    "https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf"
  ],
  "search_results": [
    {
      "title": "STABILITY TESTING OF DRUG SUBSTANCES AND ...",
      "url": "https://database.ich.org/sites/default/files/ICH_Q1EWG_Step2_Draft_Guideline_2025_0411.pdf",
      "date": "2025-04-11",
      "last_updated": "2025-08-10"
    },
    {
      "title": "Annex 10",
      "url": "https://database.ich.org/sites/default/files/Q1F_Stability_Guideline_WHO_2018.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "Annex 2 Stability testing of active pharmaceutical ...",
      "url": "http://academy.gmp-compliance.org/guidemgr/files/WHO_TRS_953_Annex2.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    },
    {
      "title": "Accelerated Predictive Stability Testing",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11858995/",
      "date": "2025-01-25",
      "last_updated": "2025-07-08"
    },
    {
      "title": "i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product- ...",
      "url": "https://asean.org/wp-content/uploads/i-Final-ASEAN-Guideline-on-Stability-Study-Drug-Product-R2_uniformed-template.pdf",
      "date": null,
      "last_updated": "2025-08-10"
    }
  ]
}